Skip to main content
IKT logo

IKT · Inhibikase Therapeutics, Inc.

Track IKT — free
$1.32 +0.02 (+1.54%) At close · Nov 20
Market Cap
$185.16M
Shares
140.27M
Volume · Nov 20 1.11M Avg daily vol (3M) 580.26K

Price & Indicators

 

Key stats

Close
$1.32
Fri 20 Nov
Open
$1.28
Fri 20 Nov
Average volume, 30 days
666K
shares a session
Short interest
19.4M
13.9% of shares · 28.6 days to cover
Day range
$1.28$1.37
Open $1.28 Close $1.32
52-week closing range
$1.30$2.52
Close $1.32 47.6% under the high
Short volume, last session
61%
Last earnings
Nov 10, 2026
Latest filing
10-Q · Nov 10
Price history
Dec 2020 to Nov 2026

Up next

Mar 25, 2027 Est · unconfirmed · in 18 wks

Latest documents

2026
Nov 16
Investor event
Safety update 2027, PVR data mid-2028, pivotal mid-2029

Inhibikase's CEO said the phase three program has 28 countries approved and 79 sites running. A safety update is planned for 2027, covering 50 patients and 12 weeks of data, with a PVR readout in mid-2028 and pivotal data in mid-2029. The 2027 update is tied to a $55 million financing.

6 source passages
We have 28 countries approved and 79 sites up and running. So in 2027, what we've communicated is that we will provide what we've called a safety update what we are obligated to do for a financing tranche is to have 50 patients into the study and 12 weeks worth of data. and then a really exciting readout for us is mid-2028. So think of that as sort of mid-2029 is when we said we'd finish the Part B of the study. That brings in a $55 million financing for us Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA grants orphan designation as Phase 3 trial advances

Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million.

Net loss $20.47M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
Following our submission of an Orphan Drug Designation (“ODD”) application to the FDA for IKT-001 for PAH in April 2026, the FDA's Office of Orphan Products Development granted ODD for IKT-001 in July 2026. Our Phase 3 clinical study, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), which is a single pivotal global study, is presently enrolling patients with 28 country regulatory approvals globally and 79 clinical sites activated to date, and three additional pending country regulatory approvals and one planned country regulatory submission. At September 30, 2026, we had cash, cash equivalents and marketable securities of $193.3 million. Open the document at this passage
Nov 10
Current report 8-K
IMPROVE-PAH gains 28 approvals, activates 79 sites

Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share.

Financial results
3 source passages
“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were $193.3 million. Net Loss: Net loss for the quarter ended September 30, 2026, was $20.5 million, or $0.10 per share, compared to a net loss of $11.9 million, or $0.13 per share in the quarter ended September 30, 2025. Open the document at this passage
Oct 20
Current report 8-K Events of Oct 19
Scott Wasserman joins board after Dennis Berman resigns

Inhibikase Therapeutics said Dennis Berman resigned from its board and committee roles effective October 19, 2026. The board appointed Scott Wasserman as a Class III director the same day, with options to purchase up to 310,000 shares.

Director or officer change, or executive pay, Regulation FD disclosure
4 source passages
Dennis Berman resigned from the board of directors effective as of October 19, 2026 appointed Scott Wasserman to serve as a Class III director non-qualified stock options to purchase up to 310,000 shares Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$69.17M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-26.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$193.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+118.7%
Year over year · more shares
Price change (1Y)
-13.7%
Trailing year
Short interest
13.9%
Latest settlement · 28.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −26%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return −17%
trailing
6-month return −22%
trailing
YTD return −36%
this year
Relative strength −13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.85% of shares out · ▼ -1.0% MoM · 28.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
110 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +58%
Y/Y
Free cash flow $-27.8M
Buyback $131.5M
remaining
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −48%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +13 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.85% of shares out · ▼ -1.0% MoM · 28.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
110 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 2% Range high $3
vs 200-day avg -31% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $193.3M As of September 30, 2026 —
Clinical sites activated for Phase 3 IMPROVE-PAH study 79 As of November 2026 —
Pre-funded warrants outstanding 60.6M As of September 30, 2026 —
Shares of common stock outstanding 140.3M As of September 30, 2026 —
clinical sites initiated for Phase 3 IMPROVE-PAH study 43 Q2 2026 —
country regulatory approvals for Phase 3 IMPROVE-PAH study 26 Q2 2026 —
planned Phase 3 IMPROVE-PAH Part A patient enrollment 140 Phase 3 IMPROVE-PAH study design —
planned Phase 3 IMPROVE-PAH Part B patient enrollment 346 Phase 3 IMPROVE-PAH study design —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IKT
Inhibikase Therapeutics, Inc.
this stock
$185.16M -35.6% -100.0% — 13.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
110
% held
90.7%
Net QoQ
+9.4M sh
Top holder
Sands Capital Alternative…
Held Float
View
Held by Funds
Fund positions
83
View
Short & Settlement
Short Interest Falling
Shares short
19.4M
Days to cover
28.6d
Change
-197.3K sh
View
Short Volume
Short vol %
61%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$4.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
32.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-48.3M
EPS diluted
$-0.49
View
Buybacks
Remaining
$131.5M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
21

Inhibikase's CEO said the phase three program has 28 countries approved and 79 sites running. A safety update is planned for 2027, covering 50 patients and 12 weeks of data, with a PVR readout in mid-2028 and pivotal data in mid-2029. The 2027 update is tied to a $55 million financing.

View
Exempt Offerings
Offering
$8.0M
Filed
Jun 4, 2024
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Inhibikase Therapeutics Announces…
Published
Nov 10, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IKT -13.2% -17.0% -22.4% -14.8% -35.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.6% -7.8% -13.2% -6.1% -36.8%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$131.50M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 109 filings 103 filers Visit website Investor relations